N-(1-Carboxy-3-Phenylpropyl)Phenylalanyl-Alpha-Asparagine

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
N-(1-Carboxy-3-Phenylpropyl)Phenylalanyl-Alpha-Asparagine
Accession Number
DB02307  (EXPT01770)
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
Categories
UNII
Not Available
CAS number
Not Available
Weight
Average: 441.477
Monoisotopic: 441.189985611
Chemical Formula
C23H27N3O6
InChI Key
FOJUHLDAXGNCIP-FHWLQOOXSA-N
InChI
InChI=1S/C23H27N3O6/c24-21(29)18(14-20(27)28)26-22(30)19(13-16-9-5-2-6-10-16)25-17(23(31)32)12-11-15-7-3-1-4-8-15/h1-10,17-19,25H,11-14H2,(H2,24,29)(H,26,30)(H,27,28)(H,31,32)/t17-,18-,19-/m0/s1
IUPAC Name
(2S)-2-{[(1S)-1-{[(1S)-2-carboxy-1-(C-hydroxycarbonimidoyl)ethyl]-C-hydroxycarbonimidoyl}-2-phenylethyl]amino}-4-phenylbutanoic acid
SMILES
[H][C@@](CCC1=CC=CC=C1)(N[C@@]([H])(CC1=CC=CC=C1)C(O)=N[C@@]([H])(CC(O)=O)C(O)=N)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UPseudolysinNot AvailablePseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
448836
PubChem Substance
46508508
ChemSpider
395515
HET
HPI
PDB Entries
1u4g

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0386 mg/mLALOGPS
logP0.12ALOGPS
logP-1.8ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)-1.9ChemAxon
pKa (Strongest Basic)12.51ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area163.3 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity126.3 m3·mol-1ChemAxon
Polarizability44.64 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8123
Blood Brain Barrier+0.529
Caco-2 permeable-0.83
P-glycoprotein substrateNon-substrate0.5211
P-glycoprotein inhibitor INon-inhibitor0.9004
P-glycoprotein inhibitor IINon-inhibitor0.983
Renal organic cation transporterNon-inhibitor0.9216
CYP450 2C9 substrateNon-substrate0.8079
CYP450 2D6 substrateNon-substrate0.8532
CYP450 3A4 substrateNon-substrate0.6993
CYP450 1A2 substrateNon-inhibitor0.9721
CYP450 2C9 inhibitorNon-inhibitor0.9371
CYP450 2D6 inhibitorNon-inhibitor0.8898
CYP450 2C19 inhibitorNon-inhibitor0.9567
CYP450 3A4 inhibitorNon-inhibitor0.8444
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9546
Ames testNon AMES toxic0.8184
CarcinogenicityNon-carcinogens0.9407
BiodegradationNot ready biodegradable0.7086
Rat acute toxicity1.8533 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9865
hERG inhibition (predictor II)Non-inhibitor0.9116
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Dipeptides
Alternative Parents
Phenylalanine and derivatives / Aspartic acid and derivatives / N-acyl-alpha amino acids and derivatives / Alpha amino acid amides / L-alpha-amino acids / Amphetamines and derivatives / Aralkylamines / Fatty amides / Dicarboxylic acids and derivatives / Secondary carboxylic acid amides
show 7 more
Substituents
Alpha-dipeptide / Phenylalanine or derivatives / Aspartic acid or derivatives / N-acyl-alpha amino acid or derivatives / Alpha-amino acid amide / Alpha-amino acid / N-substituted-alpha-amino acid / Alpha-amino acid or derivatives / Amphetamine or derivatives / L-alpha-amino acid
show 23 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
Pharmacological action
Unknown
General Function
Metalloendopeptidase activity
Specific Function
Cleaves host elastin, collagen, IgG, and several complement components as well as endogenous pro-aminopeptidase (PubMed:11533066). Autocatalyses processing of its pro-peptide (PubMed:9642203, PubMe...
Gene Name
lasB
Uniprot ID
P14756
Uniprot Name
Elastase
Molecular Weight
53686.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Drug created on June 13, 2005 07:24 / Updated on September 02, 2019 17:18